drugset / Trial / NCT02103998
Study of Thyroid Hormones in Prematures
Phase 3
Withdrawn
New York Medical College
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedSingle-groupTriple-blindTreatment
Summary
The investigators hypothesize that continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days from birth will reduce by 30% or more (from an estimated 30% to 21%) the proportion of extremely low gestational age subjects with a composite endpoint of "cerebral palsy (CP) or a Bayley III Composite Cognitive Score \< 85" at 36 months corrected postnatal age (CA).
Timeline
- Start
- 2020-07-01
- Primary completion
- 2025-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levothyroxine | Other / unclassified | 4 ug/kg | — |
| Subject | potassium iodide | Unknown | 30 ug/kg | Oral |